Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Overview
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Companies Involved in Therapeutics Development
HK inno.N Corp
KinDex Pharmaceuticals Inc
MorphoSys AG
Novopyxis Inc
Vicore Pharma AB
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Drug Profiles
(amlodipine besylate + valsartan) + atorvastatin calcium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDT-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-6A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
thalidomide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Dormant Products
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Discontinued Products
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Product Development Milestones
Featured News & Press Releases
Jun 11, 2021: Vicore announces FDA acceptance for pivotal phase 3 trial of C21 in COVID-19
Apr 20, 2021: Vicore Pharma to host Key Opinion Leader webir on C21 for the treatment of COVID-19
Mar 11, 2021: Vicore Pharma’s drug candidate C21 dilates peripheral resistance vessels in fibrotic disease
Feb 01, 2021: Vicore Pharma Holding: Positive data from Phase II study ATTRACT in patients with COVID-19 published online
Dec 21, 2020: Vicore Pharma: Positive results show that C21 can become an important complement to COVID-19 vaccines
Dec 15, 2020: Vicore Pharma announces last patient last visit in the mechanistic phase II study with C21 in systemic sclerosis
Dec 08, 2020: Vicore Pharma’s oral C21 provides clinical improvement in Covid-19 trial
Nov 16, 2020: Vicore Pharma recruits the first patient in the phase II Proof-of-Concept study in idiopathic pulmory fibrosis
Oct 01, 2020: Vicore Pharma announces completion of patient enrollment in the COVID-19 ATTRACT trial
Sep 25, 2020: Robust effects of VP01 in human idiopathic pulmory fibrosis lung tissue
Aug 25, 2020: Vicore Pharma restarts mechanistic study with VP01 in systemic sclerosis
Jul 27, 2020: Vicore Pharma doses first COVID-19 patient in the ATTRACT study in India
Jun 23, 2020: Vicore Pharma expands recruitment base for the ATTRACT study
Jun 22, 2020: Vicore Pharma’s drug candidate VP01 demonstrates potential for significant benefit in severe pulmory hypertension
May 29, 2020: LifeArc awards ? 1.5 million grant to Vicore Pharma for the VP01 COVID-19 clinical study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by HK inno.N Corp, 2021
Pipeline by KinDex Pharmaceuticals Inc, 2021
Pipeline by MorphoSys AG, 2021
Pipeline by Novopyxis Inc, 2021
Pipeline by Vicore Pharma AB, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021